Cytokine response to group B streptococcus infection in mice

Scandinavian Journal of Immunology

Volumn 47, Issue 4, 1998, Pages 314-323

  Rosati, E ^a   Fettucciari, K ^a   Scaringi, L ^a   Cornacchione, P ^a   Sabatini, R ^a   Mezzasoma, L ^a   Rossi, R ^a   Marconi, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOREACTIVITY; IMMUNOREGULATION; INFECTION RESISTANCE; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION;

EID: 0031955203     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00305.x     Document Type: Article

References (63)

1. Baker CJ, Edwards MS. Group B streptococcal infections. Perinatal impact and prevention methods. Ann NY Acad Sci 1988; 549:193-202.
2. Ferrieri P. GBS infection in newborn infants: diagnosis and treatment. Antibiot Chemother 1985; 35:211-24.
3. Baker CJ. Group B streptococcal infections in newborns. N Engl J Med 1986; 314:1702-8.
4. Givner LB, Baker CJ. The prevention and treatment of neonatal group B streptococcal infections. In: Aronoff SC, Hughes WT, Kohl S, Speck WT, Wald ER. eds. Advances in Pediatric Infectious Diseases. Vol. 3. Chicago: Year Book Medical Publishers, 1988:65-90.
5. Gotoff SP, Boyer KM. Cellular and humoral aspects of host defense mechanism against GBS. Antibiot Chemother 1985; 35:142-56.
6. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753-6.
7. Edwards MS, Buffone GJ, Fuscher PA, Weeks JL, Baker CJ. Deficient classical complement pathway activity in newborn sera. Pediatr Res 1983; 17:685-7.
8. Becker ID, Robinson OM, Bazan TS, Lopez-Osuna M, Kretschmer RR. Bactericidal capacity of newborn phagocytes against group B beta-hemolytic streptococci. Infect Immun 1981; 13:535-9.
9. Paul WE, Seder RA. Lymphocyte response and cytokines. Cell 1994; 76:241-51.
10. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Ann Rev Biochem 1990; 59:783-836.
11. Trinchieri G, Kubin M, Bellone G, Cassatella MC. Cytokine crosstalk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity. J Cell Biochem 1993; 53:301-8.
12. Arditi M, Manogue KR, Caplan MM, Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor-α and platelet activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990; 162:139-47.
13. Gibson RL, Redding GJ, Henderson WR, Truog WE. Group B streptococcus induces tumor necrosis factor in neonatal piglets. Effect of the tumor necrosis factor inhibitor pentoxifylline on hemodynamics and gas exchange. Am Rev Respir Dis 1991; 143:598-604.
14. Teti G, Mancuso G, Tomasello F, Chiofalo MS. Production of TNF and IL-6 in mice infected with group B streptococci. Circ Shock 1992; 38:138-44.
15. Teti G, Mancuso G, Tomasello F. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun 1993; 61:227-35.
16. Williams PA, Bohnsack JF, Augustine NH, Drummond WK, Rubens CE, Hill HR. Production of tumor necrosis factor by human cells in vitro and in vivo induced by group B streptococci. J Pediatr 1993; 123:292-300.
17. Wennerstrom DE, Shutt RW. Adult mice as a model for early onset group B streptococcal disease. Infect Immun 1978; 19:741-4.
18. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493-7.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
20. Sambrook J, Fritsch EF, Maniatis T. In: Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor NY: Cold Spring Harbor Laboratory Press, 1989.
21. Lee HJ, Koyano-Nakagawa N, Naito Y et al. cAMP activates the IL-5 promoter synergistically with phorbol ester through the signaling pathway involving protein kinase A in mouse thymoma line EL-4. J Immunol 1993; 151:6135-42.
22. Rottenberg ME, Sunnemark T, Leandersson T, Örn A. Organ-specific regulation of interferon-γ, interleukin-2 and interleukin-2 receptor during murine infection with Trypanosoma cruzi. Scand J Immunol 1993; 37:559-68.
23. Wollenberg GK, DeForge LE, Bolgos G, Remick DG. Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 1993; 143:1121-30.
24. Fuhlbrigge RC, Chaplin DD, Kiely JM, Unanue ER. Regulation of interleukin-1 gene expression by adherence and lipopolysaccharide. J Immunol 1987; 138:3799-802.
25. Metcalf D. The role of the colony-stimulating factors in resistance to acute infections. Immunol Cell Biol 1987; 65:35-43.
26. Thorens B, Mermod J, Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttrascriptional regulation. Cell 1987; 48:671-9.
27. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon-γ by an intracellular parasite and induces resistance in T-cell-deficient host. Proc Natl Acad Sci USA 1993; 90:6115-9.
28. Henkel G, Weiss DL, McCoy R, Deloughery T, Tara D, Brown MA. DNase I-hypersensitive site in the second intron of the murine IL-4 gene defines a mast cell-specific enhancer. J Immunol 1992; 149:3239-46.
29. Rosati E, Scaringi L, Cornacchione P et al. Activation of cytokine genes during primary and anamnestic immune response to inactivated C. albicans. Immunology 1996; 89:142-51.
30. Marconi P, Scaringi L, Tissi L et al. Induction of natural killer cell activity by inactivated Candida albicans in mice. Infect Immun 1985; 50:297-303.
31. Cassone A, Marconi P, Bistoni F et al. Immunoadjuvant effects of Candida albicans and its cell wall fractions in a mouse lymphoma model. Cancer Immunol Immunother 1981; 10:181-90.
32. Lodder J, The Yeast, a Taxonomic Study. 2nd ed. North-Holland: Amsterdam, The Netherlands, 1970:914-32.
33. Cassone A, Torosantucci A. Immunological moieties of the cell wall. In: Prasad R, ed. Candida albicans. Springer-Verlag: Berlin/Heidelberg, 1991:89-106
34. Bistoni F, Baccarini M, Blasi E, Puccetti P, Marconi P. A radiolabel release microassay for phagocytic killing of Candida albicans. J Immunol Methods 1982; 52:369-77.
35. Cerottini FC, Branner KT. Cell mediated cytotoxicity allograft rejection and tumor immunity. Adv Immunol 1974; 18:67-122.
36. Mattes MJ, Sharrow SO, Herberman RB, Holden HT. Identification and separation of Thy1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Immunol 1979; 123:2851-60.
37. Thorn RM, Henney CS. Kinetics of target cell destruction by effectors T cells. I. Delineation of parameters related to the frequence and lytic efficiency of killer cells. J Immunol 1976; 117:2213-8.
38. O'Garra A, Howard M. IL-10 production by CD5 B cells. Ann NY Acad Sci 1992; 651:182-99.
39. Broski AP, Halloran PF. Tissue distribution of IL-10 mRNA in normal mice. Transplantation 1994; 57:582-92.
40. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143:2894-9.
41. Liu Z, Simpson RJ, Cheers C. Interactions of interleukin-6, tumor necrosis factor and interlcukin-1 during Listeria infection. Immunology 1995; 85:562-7.
42. Nacy CA, Meierovics AI, Belosevic M, Green SJ. Tumor necrosis factor-α: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathology 1991; 59:182-7.
43. Heinzel FP, Sadick MD, Mutha SS, Locksley RM. Production of interferon-γ, interleukin-2, interleukin-4 and interleukin-10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991; 88:7011-5.
44. H1 responses with acquired resistance. Infect Immun 1991; 59:4647-54.
45. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (chachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 58:2563-9.
46. Denis M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J Leuk Biol 1991; 50:495-501.
47. Gazzinelli RT, Wysocka M, Hayashi S et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994; 153:2533-43.
48. Cusumano V, Genovese F, Mancuso G, Carbone M, Fera MT, Teti G. Interleukin-10 protects neonatal mice from lethal group B streptococcal infection. Infect Immun 1996; 64:2850-2.
49. Cusumano V, Mancuso G, Genovese F et al. Role of gamma interferon in a neonatal mouse model of group B streptococcal disease. Infect Immun 1996; 64:2941-4.
50. Mancuso G, Tomasello F, Migliardo M et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994; 62:4979-5002.
51. Derrico CA, Goodrum KJ. Interleukin-12 and tumor necrosis factor alpha mediate innate production of gamma interferon by Group B streptococcus-treated splenocytes of severe combined immunodeficiency mice. Infect Immun 1996; 64:1314-9.
52. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptative immunity. Annu Rev Immunol 1995; 13:251-76.
53. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in Leishmaniasis. J Immunol 1995; 154:5320-30.
54. Valentin Weigand P, Benkel P, Rohde M, Chhatwal GS. Entry and intracellular survival of group B streptococci in J774 macrophages. Infect Immun 1996; 64:2467-73.
55. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991; 5:171-7.
56. H1 clones. J Exp Med 1989; 170:2081-95.
57. Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell 1994; 76:323-32.
58. Reiner NE. Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. Immunol Today 1994; 15:374-8.
59. Martin TR, Ruzinski JT, Rubens CE, Chi EY, Christopher BW. The effect of type-specific polysaccharide capsule on the clearance of group B streptococci from lungs of infant and adult rats. J Infect Dis 1992; 165:306-14.
60. Noel GJ, Katz SL, Edelson PJ. The role of C3 in mediating binding and ingestion of group B streptococcus serotype III by murine macrophages. Pediatr Res 1991; 30:118-23.
61. Goodrum KJ, Dierksheide J, Yoder BJ. Tumor necrosis alpha acts as an autocrine second signal with gamma interferon to induce nitric oxide in group B streptococcus-treated macrophages. Infect Immun 1995; 63:3715-7.
62. Goodrum KJ, McCormick LL, Schneider B. Group B streptococcus-induced nitric oxide production in murine macrophages is CR3 (CD11b/CD18) dependent. Infect Immun 1994; 62:3102-7.
63. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4:2860-7.